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Abstract: Lymphatic filariasis (LF)-related disability af-
fects 40 million people globally, making LF the leading
cause of physical disability in the world. Despite this, there
is limited research into how the impacts of LF-related
disability are best measured. This article identifies the
tools currently being used to measure LF-related disability
and reviews their applicability against the known impacts
of LF. The findings from the review show that the generic
disability tools currently used by LF programs fail to
measure the majority of known impacts of LF-related
disability. The findings from the review support the
development of an LF-specific disability measurement
tool and raise doubt about the suitability of generic
disability tools to assess disability related to neglected
tropical diseases (NTDs) globally.
Background
Lymphatic filariasis (LF) is caused by three filarial nematodes:
Brugia malayi, Brugia timori, and most commonly, Wucheria bancrofti [1].
Globally 120 million people have LF and 1.34 billion people are at
risk within endemic regions (65% within South-East Asia, 30% in the
African region, and the remaining in other tropical regions) [2].
It is estimated that 40 million people are chronically disabled by
LF, making LF the leading cause of physical disability in the world
[3]. In the chronic stages, LF can cause severe lymphoedema of limbs
and genitalia, scrotal hydrocele, rheumatic, and respiratory problems
[4]. Lymphoedema affects approximately 15 million people, whilst
scrotal hydrocele affects approximately 25 million men globally [2].
The Global Program to Eliminate Lymphatic Filariasis
(GPELF) recently released their progress report for 2000–2009
[2]. The report summarized the work of the GPELF’s first decade,
which was focused on implementing mass drug administration
(MDA) across all LF endemic regions. The report acknowledged
that whilst MDA programmes have been particularly successful in
reducing infection within communities, efforts to reduce morbidity
associated with LF remain lacking. Currently, only 26 of the 81
endemic countries have morbidity programs [2]. These programs
focus on hygiene, skin care, hydrocele surgery, and exercises [5].
The GPELF plan for 2010–2020 highlights the need for the
establishment of morbidity management programs in all endemic
regions. In particular, the plan identifies the need for the
development of metrics to monitor and report on the outcomes
of these programs [2].
Globally, the approach to disability measurement has shifted
over the past two decades. Previously, disability and the impact of
disease were conceptualized using a medical model. Measures of
mortality, years living with impairment [6], or in the case of LF,
the stage and type of impairment [2] reflected a purely medical
model to health measurement. However, in recent years, the
concept of health and wellness has expanded. Disability is now
conceptualised not as the presence of an illness or impairment but
rather as the relationship between the disease/illness/impairment,
the persons functioning within daily activities/social roles, and the
social, cultural, and physical environments that enable or limit an
individual’s ability to participate fully in his or her community and
daily lives [7]. As a result, global disability measurement tools have
been developed to measure these broad concepts.
Within the LF community, a number of generic disability tools
have been recommended and trialled. These include The
International Classification of Functioning, Disability and Health
(ICF) [8], the WHO Disability Assessment Schedule (WHODAS)
(J.M. Fox, personal communication, 2012) [9,10], and the WHO
Quality of Life Tools (WHOQOL and WHOQOL-Bref) [11].
These generic tools are suggested to be necessary and appropriate
measures of disability impact for LF as they have been developed
and validated internationally (allowing for multi-country surveys)
and would allow comparison of findings against other diseases
(allowing for the GPELF to potentially raise the awareness of the
impacts of LF globally) [8].
However, others have advocated for the development of an LF-
specific disability measurement tool, arguing that an LF-specific
tool would be more sensitive to the clinical features of LF and for
detecting small changes in function that occur with disease
progression [12]. Further, it has been argued that an LF-specific
tool would allow greater sensitivity in the assessment of outcomes
of GPELF interventions, particularly for patients in chronic stages
of the disease where the physical impacts are irreversible and
quality of life rather than cure becomes the aim of intervention
[11].
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In order to determine if current generic tools are suitable for
disability measurement within LF programs, this article aims to
summarize the reported issues of LF-related disability and review
generic tools being used for LF measurement for relevance to these
known issues of LF disability.
Methods
A database search of MEDLINE, CINAHL, Scopus, and
ProQuest databases was conducted to identify disability measure-
ment tools that had been used to measure LF-related disability.
Keywords used in the search (both separately and in Boolean
combination) included but was not limited to: ‘‘lymphatic filariasis,’’
‘‘elephantiasis,’’ ‘‘lymphoedema,’’ ‘‘lymphocele,’’ ‘‘hydrocele,’’ ‘‘dis-
ability,’’ ‘‘rehabilitation,’’ ‘‘morbidity,’’ ‘‘evaluation,’’ ‘‘measure-
ment,’’ ‘‘assessment,’’ ‘‘monitoring,’’ ‘‘severity of illness,’’ ‘‘exami-
nation,’’ and ‘‘health screening.’’ Grey literature was also reviewed.
Inclusion criteria were as follows: (a) the tools measured the
experience of disability from a patient perspective and (b) the tools
measured the lived experience or impacts of LF-related disability
rather than solely the physical or medical attributes of the disease.
Exclusion criteria were as follows: (a) tools that measured the
clinicians’ perspective of disability rather than the patients’, (b) tools
that measured solely medical issues of LF-related disability rather
than the impact/experience of living with LF-related disability, and
(c) survey instruments were specific to study rather than psycho-
metrically tested generic disability tools for generic disability
measurement. From the search, 12 studies were identified that
had used generic disability measures, of which five were excluded as
they were non-standardized, self-developed research questionnaires
rather than psychometrically tested generic disability instruments.
The questions included in each tool used for LF measurement
were reviewed against the key issues of LF-related disability as
reported in the literature (see Table 1). These known issues are
taken from a previous critical review of the qualitative research
into the experiences of people living with LF-related disability
[13]. Issues of LF-related disability were included in the review if
they were found to be central to the experience of LF-related
disability in two or more studies. Key issues that were only
identified within one study were not included in the review, as it
was hypothesized that these issues may have been relevant to the
context of the single study, rather than a key issue of LF-related
disability within other regions/populations. Content analysis of
the key issues was then completed by the research team to
identify broad themes, referred to as ‘‘domains’’ within this study.
Findings
Issues of LF-Related Disability
The most commonly reported issues relevant to LF-related
disability were impact of LF on work (nine studies), stigma
surrounding LF within local communities (nine studies), impact
on personal relationships (nine studies), depression (seven studies),
impact of LF on social events (seven studies), feelings of shame/
humiliation experienced by LF patients (six studies), fear (six
studies), and reduced social status (six studies) (see Table 1). Least
commonly reported issues (reported in one study only) relevant to
LF-related disability were feelings of inadequacy, feeling like a
burden, sleeping problems, location of treatment, stigma within
the school system, access to appropriate foot-care, un-hygienic
home conditions, and un-hygienic work conditions.
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Disability Measurement Tools Currently Used for LF
Morbidity Measurement
Three tools have been previously used to measure LF-related
disability: The seven domains five levels (7D5L) instrument, which
is a seven-item, extended form of the European Quality of Life
Instrument (EuroQol 5D3L) [14,15]; The Dermatology Life
Quality Index (DLQI) [16–19], a 10-item tool designed to
measure the impact of skin disease on quality of life (QOL); and
The ICF checklist [8], a multi-item checklist based on the WHO
ICF social model of health [8,20].
Another three tools have either been advocated for use in LF
measurements or have been used for LF disability surveys but have
not been formally published [9]. These are the WHO Quality of
Life tool (WHOQOL), a hundred-item QOL measurement
[11,21]; the WHOQOL Bref [11,22], which is a shortened (26-
item) version of the WHOQOL tool; and the WHO Disability
Assessment Schedule (WHODAS) [9,10,23], a 36-item disability
measurement tool.
Relevance of Generic Tools to LF-Related Disability Issues
The 34 issues reported by people living with LF-related
disability were compared against the items from each of the six
disability measurement tools (see Table 2). Some items within the
tools measure broad concepts (i.e., ‘‘usual activity’’ item of the
7D5L tool) that relate to a range of issues within the activity
domain (however did not specifically represent any of the separate
issues). Of the 34 issues reported to be relevant for people living
with LF, 11 would not be identified by any of the current
measurement tools (feelings of shame/humiliation, low self-
esteem/feeling of inferiority, ability of cope, grief, fear, frustration,
work agitates condition, teasing by others, avoided by others,
families becoming carers, and lack of access to support groups).
Content analysis revealed five broad domains that the issues
encompassed. These were psychological impacts, impact on daily
activities, impact on participation, and the influence of environ-
mental factors and personal factors. In total, the domains that
would most comprehensively be assessed by the tools items were
found to be daily activities (tools covered 37.5%–75% of issues),
participation (tools covered 33%–100% of issues), and personal
factors (tools covered 33%–100% of issues). More poorly
measured by the tools were psychological issues (tools covered
0%–20% of issues) and environmental factors (tools covered 0%–
60% of issues) relevant to LF-related disability.
The ICF checklist was found to have items that captured the
most issues (50%), followed by the WHODAS 36 (47%). However,
neither of these tools included any items that would identify the 10
specific issues included within the psychological domain. The
other tools had very few items that would identify issues related to
LF disability: 7D5L (29%), WHO-QOL 100 (28%), DLQI (24%),
and WHOQOL Bref (22%).
Discussion
The research that informs our knowledge of the impact of LF-
related disability is limited and still emerging [13]. However, key
issues of LF-related disability have been found across studies
within multiple countries, suggesting that these issues are relevant
and common to LF patients globally. The findings reveal that the
greatest number of issues/impacts of LF-related disability falls
within the environmental and psychological domains—two areas
of need where GPELF has failed to develop intervention strategies.
Whilst the GPELF continues to identify prevention and alleviation
of disability as a key second pillar of the program [24], there is
limited movement and financial support within the program to
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develop substantial rehabilitation programmes that (a) support
mental health and well-being, (b) minimize barriers from stigma
through advocacy work, (c) provide adequate intervention for
those living with chronic LF to prevent further disease progression,
and (d) assist in re-engagement with daily activities and life roles
that are important for patients both physically, mentally, and
socially.
This review identified that the tools currently being used to
measure LF-related disability are inadequate. This review revealed
34 issues across five domains that are consistently reported by
people living with LF-related disability. Of the six measurement
tools (four generic, two specific) that have been used to measure
LF-related disability, only one measurement tool (ICF Checklist
[8]) included 50% of relevant issues, whilst others covered between
22% and 47% of the known issues of LF-related disability. Hence,
current disability measurement tools used within the field fail to
measure at least half of the known impacts of LF-related disability.
Importantly, the majority of tools do not measure the most
commonly reported issues of LF-related disability. The most
commonly reported psychological issues, feelings of shame/
humiliation, low self-esteem, and fear are not measured by any
tools. Likewise, the most commonly reported environmental issues
are not well measured by the tools; teasing is not measured by any
tool, whilst the impact on social status is captured by one tool and
stigma within family and stigma within communities are measured
within two tools. However, impact of LF on work and personal
relationships, two of the most commonly reported impacts of LF,
are measured by all tools.
Whilst generic disability tools have been developed to capture
social and functional impacts of disease, the tools reviewed in this
article were inadequate to measure the majority of the known
impacts of LF. Indeed other authors have reported that generic
tools often do not capture disease-specific aspects and are
insensitive to detecting key changes in patient status making them
poor outcome measurement tools for disease-specific studies [25–
27]. Generic tools, such as the ICF, WHOQOL, and WHODAS,
whilst useful for comparison studies between diseases, will not
effectively measure the impacts of LF and outcomes of GPELF
programs. If they are the only tools used by public health planners
to capture the impact of LF, they are likely to underestimate the
true impacts of LF globally and be poor measures of the success of
GPELF programs within LF endemic regions.
Conclusion
The ability to measure LF disability progression and the impact
of interventions over time in a standardized manner is essential for
the GPELF. The development of an LF-specific disability
assessment tool, relevant for LF impact and the contexts and
cultures of LF endemic areas, is vital for accurate GPELF
reporting and measurement. A focus on the second pillar of the
GPELF program, morbidity management, is increasingly required
as MDA programs finish. Valid and reliable information about
patient and community needs and the measurement of outcomes
of the second pillar of the GPELF program are required to ensure
best management for the prevention and alleviation of LF-related
disability.
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